{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:59:50Z","timestamp":1767920390359,"version":"3.49.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T00:00:00Z","timestamp":1404864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This non\u2010comparative phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study (<jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>linical<jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>rials.gov: <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00715208) evaluated bortezomib in place of vincristine in established rituximab\u2010chemotherapy regimens in relapsed\/refractory follicular (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>) or marginal zone lymphoma (<jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content>). Patients were allocated (physician\/patient preference) to receive six 21\u2010d cycles of: bortezomib 1\u00b76\u00a0mg\/m<jats:sup>2<\/jats:sup> (days 1, 8), rituximab 375\u00a0mg\/m<jats:sup>2<\/jats:sup> (day 1), cyclophosphamide 1000\u00a0mg\/m<jats:sup>2<\/jats:sup> (day 1) and prednisone 100\u00a0mg (days 1\u20135; <jats:styled-content style=\"fixed-case\">VR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>; 47 <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, 1 <jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content> patients); or bortezomib, rituximab, prednisone per <jats:styled-content style=\"fixed-case\">VR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>, cyclophosphamide 750\u00a0mg\/m<jats:sup>2<\/jats:sup> and doxorubicin 50\u00a0mg\/m<jats:sup>2<\/jats:sup> (day 1; <jats:styled-content style=\"fixed-case\">VR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CAP<\/jats:styled-content>; 4 <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, 2 <jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content>, 1 chronic lymphocytic leukaemia patients). With <jats:styled-content style=\"fixed-case\">VR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>, the response rate was 77%, with a 27% complete response rate. After a median follow\u2010up of 10\u00b79\u00a0months, 40% of patients had relapsed\/progressed or died. Median duration of response and progression\u2010free survival was 21\u00b79 and 14\u00b79\u00a0months, respectively. Common drug\u2010related grade \u22653 adverse events were neutropenia (25%), thrombocytopenia (6%) and lymphopenia (6%). Thirteen (27%) patients reported peripheral neuropathy (one grade 3). With <jats:styled-content style=\"fixed-case\">VR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CAP<\/jats:styled-content>, one <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> patient achieved complete response and three <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> and two <jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content> patients achieved partial responses. Three patients reported drug\u2010related grade 1\/2 peripheral neuropathy. Weekly bortezomib and rituximab represents an active, feasible treatment platform in <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">VR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content> was active and well tolerated in patients with relapsed\/refractory <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12991","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T09:25:32Z","timestamp":1404897932000},"page":"920-928","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase <scp>II<\/scp> study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma"],"prefix":"10.1111","volume":"166","author":[{"given":"Michael","family":"Craig","sequence":"first","affiliation":[{"name":"Mary Babb Randolph Cancer Center West Virginia University Robert C Byrd Health Science Center Morgantown WV USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahid T.","family":"Hanna","sequence":"additional","affiliation":[{"name":"University of Tennessee Cancer Institute Knoxville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"Hematology Auxilio Mutuo Cancer Centre San Juan Puerto Rico USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien\u2010Shing","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Loma Linda University School of Medicine Loma Linda CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dixie\u2010Lee","family":"Esseltine","sequence":"additional","affiliation":[{"name":"Millennium: The Takeda Oncology Company Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Neuwirth","sequence":"additional","affiliation":[{"name":"Millennium: The Takeda Oncology Company Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies Columbia University Medical Center New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08340.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25792"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.03.006"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3069"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq416"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-233155"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr388"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1844"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22099"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25509"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07775.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1498"},{"issue":"7","key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"vii151","DOI":"10.1093\/annonc\/mdq287","article-title":"Follicular lymphoma","volume":"21","author":"Ghielmini M.","year":"2010","journal-title":"Annals of Oncology"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06378.x"},{"key":"e_1_2_9_23_1","first-page":"w13247","article-title":"Diagnosis and treatment of follicular lymphoma","volume":"141","author":"Hitz F.","year":"2011","journal-title":"Swiss Medical Weekly"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_2_9_26_1","first-page":"1136","article-title":"The proteasome inhibitor PS\u2010341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma M.H.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2647"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050419"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24518"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.015"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.346"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1422-5"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1142"},{"key":"e_1_2_9_39_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0129","article-title":"Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice","volume":"8","author":"Rummel M","year":"2010","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5586"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.6594"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-14"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21166"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26660"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001537"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404959"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12991","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:04:54Z","timestamp":1696287894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,9]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/bjh.12991"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12991","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,9]]},"assertion":[{"value":"2013-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}